[Skip to Navigation]
Article
September 1987

Metoclopramide Response in Patients With Progressive Systemic Sclerosis: Effect on Esophageal and Gastric Motility Abnormalities

Author Affiliations

From the Division of Gastroenterology, Departments of Medicine (Drs Johnson and Chobanian), Nuclear Medicine (Drs Drane and Karvelis), and Rheumatology (Dr Curran), Naval Hospital, the Division of Gastroenterology, Department of Medicine, Uniformed Services of the Health Sciences (Drs Johnson and Chobanian), Bethesda, Md; and the Division of Gastroenterology, Department of Medicine, Georgetown University Hospital, Washington, DC (Drs Benjamin and Cattau).

Arch Intern Med. 1987;147(9):1597-1601. doi:10.1001/archinte.1987.00370090075014
Abstract

• Twelve patients with progressive systemic sclerosis (four with CREST [calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia] variant) underwent systematic evaluation to assess the esophagogastric effects of metoclopramide hydrochloride in this patient population. Esophageal manometry, esophageal radionuclide scintigraphy, solid-phase gastric emptying, and 24-hour esophageal pH monitoring were performed in all patients with and without metoclopramide. Metoclopramide improved lower esophageal sphincter pressure and reduced the gastric emptying delay and gastroesophageal reflux in most patients but had a less consistent effect improving esophageal transit or esophageal body pressures. Metoclopramide should be strongly considered in the pharmacologic approach to the gastroesophageal reflux-related complications of this disease.

(Arch Intern Med 1987;147:1597-1601)

×